Automated quantitative drug susceptibility testing of non-tuberculous mycobacteria using MGIT 960/EpiCenter TB eXiST

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 154-158

  Lucke, Katja ^a   Hombach, Michael ^a   Friedel, Ute ^a   Ritter, Claudia ^a   Böttger, Erik C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antibiotic susceptibility; Clinical isolates; Drug resistance

Indexed keywords

AMIKACIN; CLARITHROMYCIN; ETHAMBUTOL; OFLOXACIN; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIUM ISOLATE; DRUG SENSITIVITY; DRUG SUSCEPTIBILITY TESTING; IN VITRO STUDY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM KANSASII; NONHUMAN; RADIOMETRY; SCREENING TEST; ATYPICAL MYCOBACTERIOSIS; AUTOMATION; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MYCOBACTERIUM INTRACELLULARE AVIUM;

ANTITUBERCULAR AGENTS; AUTOMATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; MYCOBACTERIUM KANSASII;

EID: 84859169925     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr399     Document Type: Article

References (26)

1. Alcaide F, Calatayud L, Santin M et al. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004; 48: 4562-5.
2. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes:Approved Standard M24-A. NCCLS, Wayne, PA, USA, 2003.
3. Siddiqi SH, Heifets LB, Cynamon MH et al. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol 1993; 31: 2332-8.
4. Woods GL, Williams-Bouyer N, Wallace RJ Jr et al. Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex. J Clin Microbiol 2003; 41: 627-31.
5. Pfyffer GE, Welscher HM, Kissling P et al. Comparison of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. J Clin Microbiol 1997; 35: 364-8.
6. Tortoli E, Benedetti M, Fontanelli A et al. Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion. J Clin Microbiol 2002; 40: 607-10.
7. Rogall T, Flohr T, Bottger EC. Differentiation of Mycobacterium species by direct sequencing of amplified DNA. J Gen Microbiol 1990; 136: 1915-20.
8. Telenti A, Marchesi F, Balz M et al. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 1993; 31: 175-8.
9. Kasperbauer SH, Daley CL. Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin Respir Crit Care Med 2008; 29:569-76.
10. Springer B, Lucke K, Calligaris-Maibach R et al. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 2009; 47: 1773-80.
11. Altman DG, Newcombe RG. Proportions and their differences and diagnostic tests. In: Altman DG, Machin D, Bryant TN et al., eds. Statistics with Confidence. 2nd edn. London: BMJ Books, 2000; 46-8, 106-7.
12. Meier A, Kirschner P, Springer B et al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994; 38: 381-4.
13. Meier A, Heifets L, Wallace RJ Jr et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis 1996; 174: 354-60.
14. Nash KA, Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 1995; 39: 2625-30.
15. Nash KA, Inderlied CB. Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. Antimicrob Agents Chemother 1996; 40: 1748-50.
16. Pfister P, Jenni S, Poehlsgaard J et al. The structural basis of macrolide-ribosome binding assessed using mutagenesis of 23S rRNA positions 2058 and 2059. J Mol Biol 2004; 342: 1569-81.
17. Shafran SD, Talbot JA, Chomyc S et al. Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study Group. Clin Infect Dis 1998; 27: 1401-5.
18. Sison JP, Yao Y, Kemper CA et al. Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans? J Infect Dis 1996; 173: 677-83.
19. Van Ingen J, van der Laan T, Dekhuijzen R et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents 2010; 35:169-73.
20. Heifets L. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother 1996; 40: 1759-67.
21. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416.
22. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis 1988; 137: 1217-22.
23. Krishnan MY, Manning EJ, Collins MT. Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs. J Antimicrob Chemother 2009; 64: 310-6.
24. Piersimoni C, Nista D, Bornigia S et al. Evaluation of a new method for rapid drug susceptibility testing of Mycobacterium avium complex isolates by using the mycobacteria growth indicator tube. J Clin Microbiol 1998; 36: 64-7.
25. Altman DG. Inter rater agreement. In: Practical Statistics for Medical Research. London: Chapman and Hall, 1991; 403-9.
26. Griffith DE. Nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2010; 23: 185-90.